Dr. John Lester Goudreau, DO

Dr. Goudreau practices at MSU Health Care Inc. in East Lansing, Michigan.

Dr. Goudreau's NPI, 1477563096, was assigned on August 8, 2006. Dr. Goudreau graduated from Michigan State University College of Osteopathic Medicine in 1995. Dr. Goudreau holds Michigan license 5101012751.

Dr. Goudreau's primary practice is MSU Health Care Inc., at 788 Service Rd, East Lansing, MI 48824 in Ingham County. The practice phone is (517) 353-8122.

Dr. Goudreau's primary practice is MSU Health Care Inc. in East Lansing, Michigan. Dr. Goudreau is also affiliated with University of Michigan Health-Sparrow Lansing. The medical group on file is MSU Health Care Family Medicine | Clinical Center Second Floor. Dmand AI also links Dr. Goudreau to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goudreau practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Goudreau's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Goudreau is licensed in Michigan.

CMS data shows 89 Medicare services from Dr. Goudreau across 2 procedure codes in 2024, all of them office visits, for 96 Medicare patients. Medicare paid $8,721 for them. Every service was in an office.

CMS counts 96 Medicare patients who saw Dr. Goudreau in 2024. The largest group is 65 to 74, with 44 patients. 71% of them have high cholesterol, and 66% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goudreau's median patient age at 73, with 52% women.

In 2024, Dr. Goudreau wrote 1,389 Medicare Part D claims for 175 patients. 76% of them were for generic drugs. CMS names the drug for 1,213 of them, across 28 drugs with 11 or more claims each, at $941,089 in total drug cost. In 2023, CMS named 1,186 claims across 29 drugs.

Dr. Goudreau accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goudreau as offering telehealth.

Dmand AI links 27 papers to Dr. Goudreau, published from 2010 to 2022. 2016 was the busiest year, with 4. The most frequent topics are Dopamine, Dopaminergic Neurons and Mice, Inbred C57BL. Dr. Goudreau has published most often in Neurotoxicology. Dr. Goudreau's most frequent co-authors are James T. Boyd, MD, Chadwick W. Christine, MD and John C. Morgan, MD.

Dmand AI links Dr. Goudreau to 6 clinical trials, 2 of them phase 2 studies. Conditions studied include Parkinson Disease, Parkinsonian Disorders and Delusions. Open Payments lists research payments to Dr. Goudreau that name 2 trials.

CMS Open Payments shows 158 general payments to Dr. Goudreau from 26 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 44% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $51,248. It also lists 9 research payments totaling $15,344 from 2019 to 2020, naming 2 clinical trials.

Dr. Goudreau graduated from Michigan State University College of Osteopathic Medicine in 1995.